Fusarium culmorum

From WikiMD's WELLNESSPEDIA

Fusarium culmorum is a fungal species that belongs to the Fusarium genus. It is a common pathogen of cereal crops, particularly wheat, barley, and oats. This fungus is responsible for diseases such as root rot, crown rot, and Fusarium head blight, which can cause significant yield losses.

Taxonomy[edit]

The species was first described by William G. Smith in 1891. It belongs to the Fusarium solani species complex within the Fusarium genus, which is part of the Nectriaceae family in the Ascomycota division of fungi.

Morphology[edit]

Fusarium culmorum is characterized by its production of curved, multicelled macroconidia with a foot-shaped base. It also produces oval, single-celled microconidia and chlamydospores. The fungus grows rapidly on agar media, producing colonies that are white to pale pink in color.

Pathogenicity[edit]

Fusarium culmorum is a necrotrophic pathogen, meaning it kills host tissue and then feeds on the dead material. It produces a variety of mycotoxins, including deoxynivalenol and zearalenone, which can contaminate grain and pose a risk to human and animal health.

Management[edit]

Management of Fusarium culmorum involves a combination of cultural practices, such as crop rotation and residue management, and the use of resistant varieties. Fungicides can also be used, but their effectiveness can be limited due to the ability of the fungus to survive in soil and crop residues.

See also[edit]

This article is a stub related to fungus. You can help WikiMD by expanding it!


Sponsored Health Resource

W8MD weight loss success

W8MD Weight Loss, Sleep & MedSpa

Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.

GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.

Book a W8MD appointment · View GLP-1 specials

Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.